Although effective antiviral drugs are available for the treatment of influenza A
virus (IAV) infection, the need for intensified drug discovery towards antiviral active
compounds is obvious.
A polyphenol-enriched extract of Rumex acetosa L. (Polygonaceae), standardized on galloylated oligomeric proanthocyanidins, was
tested for antiviral activity against IAV in vitro using MTT, plaque reduction and hemagglutination assay. The extract inhibited IAV
replication in a dose-dependent manner. IC50 and CC50 values, as determined by MTT assay, were 2.2µg/mL and 79.2µg/mL, respectively, indicating
a CC50/IC50 selectivity ratio of 36. This antiviral activity was confirmed by plaque reduction
assay. To determine the mechanism of this antiviral effect, the extract was added
at different stages during the viral replication cycle. The strongest antiviral effect
was observed when the extract was added before adsorption of IAV to the cells, but
in high concentrations an effect was also detected when extract was added after adsorption
of IAV to and even after penetration of IAV into the cells, indicating the antiviral
effect being associated not only with viral adsorption and penetration. Structure-activity
relation of flavan-3-ols and oligomeric proanthocyanidins indicated that trihydroxylation
of ring B or alternatively galloylation at position O-3 potentiate the antiviral activity.
Detailed studies using the model compound procyanidin-B2-digallate indicated this
compound as a potent inhibitor of IAV.